Colhoun, Helen M.

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies

Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 172

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 160

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., et al. (2015) · Diabetologia

Metabolism, Diabetes, and CancerBladder and Urothelial Cancer Treatments

Cited by 158

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementAcute Ischemic Stroke Management

Cited by 137

Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications

Jeyam, A., Colhoun, H., McGurnaghan, S., Blackbourn, L., McDonald, T. J., Palmer, C. N. A., McKnight, J. A., Strachan, M. W. J., Patrick, A. W., Chalmers, J., et al. (2021) · Diabetes Care

Diabetes Management and ResearchDiabetes and associated disorders

Cited by 118

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 113

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 94

Antidrug Antibodies in Patients Treated with Alirocumab

Roth, E. M., Goldberg, A. C., Catapano, A. L., Torri, A., Yancopoulos, G. D., Stahl, N., Brunet, A., Lecorps, G., & Colhoun, H. M. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthBiosimilars and Bioanalytical Methods

Cited by 90

Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening Programme

on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative, Looker, H. C., Nyangoma, S. O., Cromie, D. T., Olson, J. A., Leese, G. P., Philip, S., Black, M. W., Doig, J., Lee, N., et al. (2013) · Diabetologia

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 80

Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

Phillip, M., Achenbach, P., Addala, A., Albanese-O’Neill, A., Battelino, T., Bell, K. J., Besser, R. E. J., Bonifacio, E., Colhoun, H. M., Couper, J. J., et al. (2024) · Diabetes Care

Diabetes and associated disordersDiabetes Management and Research

Cited by 79

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 73

Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes

on behalf of the SUMMIT Investigators, Looker, H. C., Colombo, M., Agakov, F., Zeller, T., Groop, L., Thorand, B., Palmer, C. N., Hamsten, A., de Faire, U., et al. (2015) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 66

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 63

The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1

van Eupen, M. G. A., Schram, M. T., Colhoun, H. M., Hanssen, N. M. J., Niessen, H. W. M., Tarnow, L., Parving, H. H., Rossing, P., Stehouwer, C. D. A., & Schalkwijk, C. G. (2013) · Diabetologia

Advanced Glycation End Products researchNitric Oxide and Endothelin Effects

Cited by 60

Diabetic neuropathy is a substantial burden in people with type 1 diabetes and is strongly associated with socioeconomic disadvantage: A population-representative study from Scotland

Jeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M. (2020) · Diabetes Care

Diabetes Management and ResearchDiabetic Foot Ulcer Assessment and Management

Cited by 59

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial

Bajaj, H. S., Gerstein, H. C., Rao-Melacini, P., Basile, J., Colhoun, H., Conget, I., Cushman, W. C., Dagenais, G. R., Franek, E., Hanefeld, M., et al. (2021) · The Lancet Diabetes & Endocrinology

Sexual function and dysfunction studiesDiabetes Treatment and Management

Cited by 56

Development and validation of a cardiovascular risk prediction model in type 1 diabetes

McGurnaghan, S. J., McKeigue, P. M., Read, S. H., Franzen, S., Svensson, A.-M., Colombo, M., Livingstone, S., Farran, B., Caparrotta, T. M., Blackbourn, L. A. K., et al. (2021) · Diabetologia

Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 53

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 51

The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study

on behalf of the Scottish Diabetes Research Network Epidemiology Group, McGurnaghan, S. J., Brierley, L., Caparrotta, T. M., McKeigue, P. M., Blackbourn, L. A. K., Wild, S. H., Leese, G. P., McCrimmon, R. J., McKnight, J. A., et al. (2019) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 46

Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis

Botros, F. T., Gerstein, H. C., Malik, R., Nicolay, C., Hoover, A., Turfanda, I., Colhoun, H. M., & Shaw, J. E. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 42